Business Context and Reporting Period
The submitted filing text identifies the registrant as Gemphire Therapeutics Inc., not Metavia Inc. It is an unaudited Form 10-Q for the quarter ended March 31, 2018, filed May 8, 2018. Gemphire was a clinical-stage biopharmaceutical company developing gemcabene for dyslipidemia and NAFLD/NASH. It had no approved products or revenue.
Financial Highlights
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $2.087 million | $2.223 million |
| Research and development expense | $4.977 million | $5.280 million |
| Total operating expenses | $7.064 million | $7.503 million |
| Net loss | $7.224 million | $7.496 million |
| Basic and diluted loss per share | $0.58 loss | $0.79 loss |
| Operating cash flow | $(7.236) million | $(6.223) million |
| Financing cash flow | $23.224 million | $11.472 million |
| Cash and cash equivalents at period end | $34.461 million | $29.282 million |
Because the company had no revenue, gross and operating margins are not meaningful. The operating loss was approximately 100% of the absent revenue base. Interest expense was $160,000 in Q1 2018, compared with $12,000 of net interest income in Q1 2017. No income tax expense or benefit was recorded because the company had a full valuation allowance against its deferred tax assets.
At March 31, 2018, total assets were $34.837 million, total liabilities were $14.020 million, and stockholders’ equity was $20.817 million. The balance sheet included a $10.115 million term loan at present value, consisting of $2.355 million current and $7.760 million long-term. The company reported compliance with its loan covenants.
Material Changes Versus the Prior Comparable Period
- Total operating expenses decreased $439,000, or approximately 6%, primarily because research and development expense declined $303,000 and general and administrative expense declined $136,000.
- Net loss improved by $272,000, or approximately 4%, despite the shift from net interest income to interest expense following the 2017 term loan.
- Operating cash use increased by approximately $1.013 million, or 16%, principally due to working-capital movements, including a decrease in accounts payable.
- Cash increased $15.988 million during the quarter, primarily from the February 2018 follow-on public offering. The company issued 3,592,858 common shares at $7.00 per share and received approximately $23.1 million of net proceeds.
- Shares outstanding increased from 10.633 million at December 31, 2017 to 14.232 million at March 31, 2018, reflecting significant equity dilution.
- Share-based compensation increased to $1.020 million from $836,000 in the prior-year quarter.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected cash on hand to fund operations for at least 12 months and, under its operating plan, through completion of the INDIGO-1 Phase 2b study, initiation of a dyslipidemia Phase 3 program in the second half of 2018, and completion of two NASH/NAFLD Phase 2a studies in the first half of 2019.
- Management also stated that additional capital would be required to continue development, operations, and any future commercialization. No other committed external funding source was identified.
- Expected clinical milestones included INDIGO-1 top-line data in the second quarter of 2018, NASH proof-of-concept data in the second half of 2018, and pediatric NAFLD data in the first half of 2019.
- The company had drawn $10.0 million under a Silicon Valley Bank facility with capacity for an additional $5.0 million through July 31, 2018, subject to clinical and preclinical milestones. The loan had interest-only payments through August 1, 2018, potentially extendable to February 1, 2019 if specified milestones were achieved, and matured February 1, 2021.
- If the required preclinical event did not occur by July 31, 2018, the company would be required either to maintain restricted cash equal to at least 100% of amounts owed or prepay the term loan. Prepayment could also require final-payment and success fees.
- The Pfizer license for gemcabene included potential milestone payments of up to $37 million and tiered royalties on future sales. No milestone or royalty liabilities had been recorded as of March 31, 2018 because the relevant conditions had not been met and payment capacity was uncertain.
- The company remained dependent on successful clinical development, regulatory approval, commercialization, and additional financing. It warned that failure to obtain funding could require delaying, reducing, or terminating development programs.
- There were no material legal proceedings reported, no off-balance-sheet arrangements, and management concluded that disclosure controls were effective as of March 31, 2018.
- Subsequent to quarter-end, the board approved increases to shares reserved under the inducement plan and proposed an increase to the 2015 equity plan, subject to stockholder approval.
Most Important Facts to Verify
- Confirm the correct issuer: the supplied filing is for Gemphire Therapeutics Inc., not Metavia Inc.
- Verify the timing and results of the INDIGO-1, NASH/NAFLD, and pediatric NAFLD clinical programs.
- Assess whether the company met the preclinical milestone required to avoid restricted-cash or full-prepayment treatment under the SVB term loan.
- Review projected cash runway against ongoing quarterly cash burn and the company’s stated need for additional financing.
- Evaluate dilution from the follow-on offering, outstanding stock options, and approximately 978,204 outstanding warrant shares.
- Review the terms and potential value of the Pfizer license obligations, including milestone payments and royalties.
- Confirm whether any later filing changed the company’s clinical strategy, financing position, debt status, or ability to continue as an independent business.